Non-interventional Study to analyse the tolerability and effectiveness of a chemotherapy with taxanes (Eurotere® / Eurotaxel®) on an everyday basis to treat breast cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004212

Enrollment

750

Registered

2012-07-18

Start date

2012-10-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50.9

Interventions

Group 1: single treatment regimen: Eurotere (R) Group 2: single treatment regimen: Eurotaxel 8r) Group 3: combination therapy : Eurotere (R) /Eurotaxel (R) with other medication

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: histological secured breast cancer, Age not less then 18 years, signed Patient informed consent, contraception during cytostatic therapy, oncological therapy in doctor´s practice

Exclusion criteria

Exclusion criteria: pregnancy, other oncological disease, deficient compliance, palliative treatment with taxanes in an earlier treatment except taxanes in neo- or adjuvant therapy

Design outcomes

Secondary

Measure	Time frame
Progression Free Survival (PFS), Overall Survival (OS), effect on physical ability (Questions in eCRF) - documantation period: 9 month	—

Primary

Measure	Time frame
Influence of age; BMI, comorbidities on therapy and tolerance (CTC-Criteria 2.0), therapeutic effect (RECIST)	—

Countries

Germany

Contacts

Public ContactHeribert Stiegler

OnkoDataMed GmbH

heribert.stiegler@onkodatamed.de030/64387560

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026